Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma

Korábbi kezelés

• Participant is receiving systemic steroids or immunosuppressive drugs, or is on chemotherapy

Más betegség

• Participant has other optic nerve or retinal degenerative disease causing vision loss, irrespective of whether it is currently treated or untreated.
• Participant has a history of ocular herpes zoster.
• Participant has uveitis or other ocular inflammatory disease.
• Participant has a history of malignancy
• History of use of drugs with known retinal toxicity

Egyéb

• Participant is blind in one eye;
• Participant has optic nerve atrophy
• Participant has a requirement of acyclovir
• Participant has evidence of corneal opacification or lack of optical clarity.
• Participant has diabetic macular edema and/or diabetic retinopathy.
• Participant is pregnant or lactating.

• Patients must meet all of the following criteria to join the study (all eligibility criteria must be met at the screening and baseline visits unless otherwise noted):
• Participant must be medically able to undergo the testing required in the schedule of visits
• Participant's clinical diagnosis must be consistent with glaucoma, characterized by the following features:
  • Clinical evidence of progressive retinal ganglion cell (RGC) dysfunction and degeneration using both visual field and at least one structural modality as established by: i. Glaucomatous visual field abnormality. ii. Mean deviation (MD) of -3 to -15 dB. iii. Minimum average retinal nerve fiber layer (RNFL) thickness of 60 μm and maximum average RNFL of 90 μm.
  • Residual visual field preservation including best-corrected visual acuity (BCVA) better than 20/200 in both eyes.
• Participant's glaucoma must be clinically stable, with intraocular pressure (IOP) \< 21.